1
|
Dawood AS, Elrashedy A, Nayel M, Salama A, Guo A, Zhao G, Algharib SA, Zaghawa A, Zubair M, Elsify A, Mousa W, Luo W. Brucellae as resilient intracellular pathogens: epidemiology, host-pathogen interaction, recent genomics and proteomics approaches, and future perspectives. Front Vet Sci 2023; 10:1255239. [PMID: 37876633 PMCID: PMC10591102 DOI: 10.3389/fvets.2023.1255239] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2023] [Accepted: 09/15/2023] [Indexed: 10/26/2023] Open
Abstract
Brucellosis is considered one of the most hazardous zoonotic diseases all over the world. It causes formidable economic losses in developed and developing countries. Despite the significant attempts to get rid of Brucella pathogens in many parts of the world, the disease continues to spread widely. Recently, many attempts proved to be effective for the prevention and control of highly contagious bovine brucellosis, which could be followed by others to achieve a prosperous future without rampant Brucella pathogens. In this study, the updated view for worldwide Brucella distribution, possible predisposing factors for emerging Brucella pathogens, immune response and different types of Brucella vaccines, genomics and proteomics approaches incorporated recently in the field of brucellosis, and future perspectives for prevention and control of bovine brucellosis have been discussed comprehensively. So, the current study will be used as a guide for researchers in planning their future work, which will pave the way for a new world without these highly contagious pathogens that have been infecting and threatening the health of humans and terrestrial animals.
Collapse
Affiliation(s)
- Ali Sobhy Dawood
- Engineering Laboratory for Tarim Animal Diseases Diagnosis and Control, College of Animal Science and Technology, Tarim University, Alar, Xinjiang, China
- The State Key Laboratory of Agricultural Microbiology, College of Veterinary Medicine, Huazhong Agricultural University, Wuhan, China
- Department of Medicine and Infectious Diseases, Faculty of Veterinary Medicine, University of Sadat City, Sadat City, Egypt
| | - Alyaa Elrashedy
- Department of Medicine and Infectious Diseases, Faculty of Veterinary Medicine, University of Sadat City, Sadat City, Egypt
| | - Mohamed Nayel
- Department of Medicine and Infectious Diseases, Faculty of Veterinary Medicine, University of Sadat City, Sadat City, Egypt
| | - Akram Salama
- Department of Medicine and Infectious Diseases, Faculty of Veterinary Medicine, University of Sadat City, Sadat City, Egypt
| | - Aizhen Guo
- The State Key Laboratory of Agricultural Microbiology, College of Veterinary Medicine, Huazhong Agricultural University, Wuhan, China
| | - Gang Zhao
- Key Laboratory of Ministry of Education for Conservation and Utilization of Special Biological Resources in the Western China, School of Life Sciences, Ningxia University, Yinchuan, China
| | - Samah Attia Algharib
- Engineering Laboratory for Tarim Animal Diseases Diagnosis and Control, College of Animal Science and Technology, Tarim University, Alar, Xinjiang, China
- National Reference Laboratory of Veterinary Drug Residues (HZAU) and MAO Key Laboratory for Detection of Veterinary Drug Residues (HZAU), Wuhan, China
- Department of Clinical Pathology, Faculty of Veterinary Medicine, Benha University, Toukh, Egypt
| | - Ahmed Zaghawa
- Department of Medicine and Infectious Diseases, Faculty of Veterinary Medicine, University of Sadat City, Sadat City, Egypt
| | - Muhammed Zubair
- Key Laboratory of Veterinary Biological Engineering and Technology, Institute of Veterinary Medicine, Jiangsu Academy of Agricultural Sciences, Nanjing, China
| | - Ahmed Elsify
- Department of Medicine and Infectious Diseases, Faculty of Veterinary Medicine, University of Sadat City, Sadat City, Egypt
| | - Walid Mousa
- Department of Medicine and Infectious Diseases, Faculty of Veterinary Medicine, University of Sadat City, Sadat City, Egypt
| | - Wanhe Luo
- Engineering Laboratory for Tarim Animal Diseases Diagnosis and Control, College of Animal Science and Technology, Tarim University, Alar, Xinjiang, China
| |
Collapse
|
2
|
Darbandi A, Koupaei M, Navidifar T, Shahroodian S, Heidary M, Talebi M. Brucellosis control methods with an emphasis on vaccination: a systematic review. Expert Rev Anti Infect Ther 2022; 20:1025-1035. [PMID: 35416090 DOI: 10.1080/14787210.2022.2066521] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
INTRODUCTION Brucellosis is considered as one of the main zoonotic infections and a major public health concern worldwide. The aim of the present study was to evaluate various strategies for controlling brucellosis with an especial emphasis on efficacy of vaccination. AREAS COVERED International databanks (Web of Science, PubMed, Embase) were searched for potentially relevant studies published from January 1, 2011 to March 25, 2021 using the following keywords: "Brucella", "Brucella abortus", "Brucella melitensis", "Brucella canis", "Brucella suis", "brucellosis", "Bang disease", "undulant fever", "Malta fever", "vaccination", "vaccine", and "immunization". The literature search was restricted to original articles published in English. EXPERT OPINION Various methods are employed to prevent and control brucellosis, such as removing sick animals by slaughtering, separating sick animals from the herd, and vaccination. Preventing, controlling, and eradicating brucellosis requires a lot of financial support, perseverance, and time. In order to conduct a detailed study, it is recommended that more studies be conducted in developing countries and different parts of the world.
Collapse
Affiliation(s)
- Atieh Darbandi
- Department of Microbiology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
| | - Maryam Koupaei
- Department of Microbiology and Immunology, School of Medicine, Kashan University of Medical Sciences, Kashan, Iran
| | | | - Soheila Shahroodian
- Department of Microbiology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
| | - Mohsen Heidary
- Shoushtar Faculty of Medical Sciences, Shoushtar, Iran.,Department of Laboratory Sciences, School of Paramedical Sciences, Sabzevar University of Medical Sciences, Sabzevar, Iran
| | - Malihe Talebi
- Department of Microbiology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.,Cellular and Molecular Research Center, Sabzevar University of Medical Sciences, Sabzevar, Iran
| |
Collapse
|
3
|
Gong W, Pan C, Cheng P, Wang J, Zhao G, Wu X. Peptide-Based Vaccines for Tuberculosis. Front Immunol 2022; 13:830497. [PMID: 35173740 PMCID: PMC8841753 DOI: 10.3389/fimmu.2022.830497] [Citation(s) in RCA: 29] [Impact Index Per Article: 14.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2021] [Accepted: 01/10/2022] [Indexed: 12/12/2022] Open
Abstract
Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis. As a result of the coronavirus disease 2019 (COVID-19) pandemic, the global TB mortality rate in 2020 is rising, making TB prevention and control more challenging. Vaccination has been considered the best approach to reduce the TB burden. Unfortunately, BCG, the only TB vaccine currently approved for use, offers some protection against childhood TB but is less effective in adults. Therefore, it is urgent to develop new TB vaccines that are more effective than BCG. Accumulating data indicated that peptides or epitopes play essential roles in bridging innate and adaptive immunity and triggering adaptive immunity. Furthermore, innovations in bioinformatics, immunoinformatics, synthetic technologies, new materials, and transgenic animal models have put wings on the research of peptide-based vaccines for TB. Hence, this review seeks to give an overview of current tools that can be used to design a peptide-based vaccine, the research status of peptide-based vaccines for TB, protein-based bacterial vaccine delivery systems, and animal models for the peptide-based vaccines. These explorations will provide approaches and strategies for developing safer and more effective peptide-based vaccines and contribute to achieving the WHO’s End TB Strategy.
Collapse
Affiliation(s)
- Wenping Gong
- Tuberculosis Prevention and Control Key Laboratory/Beijing Key Laboratory of New Techniques of Tuberculosis Diagnosis and Treatment, Senior Department of Tuberculosis, The 8th Medical Center of PLA General Hospital, Beijing, China
| | - Chao Pan
- State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Biotechnology, Beijing, China
| | - Peng Cheng
- Tuberculosis Prevention and Control Key Laboratory/Beijing Key Laboratory of New Techniques of Tuberculosis Diagnosis and Treatment, Senior Department of Tuberculosis, The 8th Medical Center of PLA General Hospital, Beijing, China
- Hebei North University, Zhangjiakou City, China
| | - Jie Wang
- Tuberculosis Prevention and Control Key Laboratory/Beijing Key Laboratory of New Techniques of Tuberculosis Diagnosis and Treatment, Senior Department of Tuberculosis, The 8th Medical Center of PLA General Hospital, Beijing, China
| | - Guangyu Zhao
- State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, China
- *Correspondence: Xueqiong Wu, ; Guangyu Zhao,
| | - Xueqiong Wu
- Tuberculosis Prevention and Control Key Laboratory/Beijing Key Laboratory of New Techniques of Tuberculosis Diagnosis and Treatment, Senior Department of Tuberculosis, The 8th Medical Center of PLA General Hospital, Beijing, China
- *Correspondence: Xueqiong Wu, ; Guangyu Zhao,
| |
Collapse
|
4
|
Ryskeldinova S, Zinina N, Kydyrbayev Z, Yespembetov B, Kozhamkulov Y, Inkarbekov D, Assanzhanova N, Mailybayeva A, Bugybayeva D, Sarmykova M, Khairullin B, Tabynov K, Bulashev A, Aitzhanov B, Abeuov K, Sansyzbay A, Yespolov T, Renukaradhya GJ, Olsen S, Oñate A, Tabynov K. Registered Influenza Viral Vector Based Brucella abortus Vaccine for Cattle in Kazakhstan: Age-Wise Safety and Efficacy Studies. Front Cell Infect Microbiol 2021; 11:669196. [PMID: 34290993 PMCID: PMC8288105 DOI: 10.3389/fcimb.2021.669196] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2021] [Accepted: 06/07/2021] [Indexed: 11/23/2022] Open
Abstract
A novel influenza viral vector based Brucella abortus vaccine (Flu-BA) was introduced for use in cattle in Kazakhstan in 2019. In this study, the safety and efficacy of the vaccine was evaluated in male and female cattle at different ages, and during pregnancy as a part of its registration process. Our data demonstrated that the Flu-BA vaccine was safe after prime or booster vaccination in calves (5–7 months old male and female), heifers (15–17 months old) and cows (6–7 years old) and was not abortogenic in pregnant animals. A mild, localized granuloma was observed at the Flu-BA injection site. Vaccinated animals did not show signs of influenza infection or reduced milk production in dairy cows, and the influenza viral vector (IVV) was not recovered from nasal swabs or milk. Vaccinated animals in all age groups demonstrated increased IgG antibody responses against Brucella Omp16 and L7/L12 proteins with calves demonstrating the greatest increase in humoral responses. Following experimental challenge with B. abortus 544, vaccinates demonstrated greater protection and no signs of clinical disease, including abortion, were observed. The vaccine effectiveness against B. abortus 544 infection was 75, 60 and 60%, respectively, in calves, heifers and adult cows. Brucella were not isolated from calves of vaccinated cattle that were experimentally challenged during pregnancy. Our data suggests that the Flu-BA vaccine is safe and efficacious in cattle, including pregnant animals; and can therefore be administered to cattle of any age.
Collapse
Affiliation(s)
- Sholpan Ryskeldinova
- Infectious Disease Prevention Laboratory, Research Institute for Biological Safety Problems, Gvardeiskiy, Kazakhstan
| | - Nadezhda Zinina
- Microbiology Laboratory, Research Institute for Biological Safety Problems, Gvardeiskiy, Kazakhstan
| | - Zhailaubay Kydyrbayev
- Infectious Disease Prevention Laboratory, Research Institute for Biological Safety Problems, Gvardeiskiy, Kazakhstan
| | - Bolat Yespembetov
- Microbiology Laboratory, Research Institute for Biological Safety Problems, Gvardeiskiy, Kazakhstan
| | - Yerken Kozhamkulov
- Infectious Disease Prevention Laboratory, Research Institute for Biological Safety Problems, Gvardeiskiy, Kazakhstan
| | - Dulat Inkarbekov
- Infectious Disease Prevention Laboratory, Research Institute for Biological Safety Problems, Gvardeiskiy, Kazakhstan
| | - Nurika Assanzhanova
- Infectious Disease Prevention Laboratory, Research Institute for Biological Safety Problems, Gvardeiskiy, Kazakhstan
| | - Aigerim Mailybayeva
- Infectious Disease Prevention Laboratory, Research Institute for Biological Safety Problems, Gvardeiskiy, Kazakhstan
| | - Dina Bugybayeva
- Infectious Disease Prevention Laboratory, Research Institute for Biological Safety Problems, Gvardeiskiy, Kazakhstan.,International Center for Vaccinology, Kazakh National Agrarian University (KazNAU), Almaty, Kazakhstan
| | - Makhpal Sarmykova
- Microbiology Laboratory, Research Institute for Biological Safety Problems, Gvardeiskiy, Kazakhstan
| | - Berik Khairullin
- Infectious Disease Monitoring Laboratory, Research Institute for Biological Safety Problems, Gvardeiskiy, Kazakhstan
| | - Kairat Tabynov
- International Center for Vaccinology, Kazakh National Agrarian University (KazNAU), Almaty, Kazakhstan.,Preclinical Research Laboratory With Vivarium, M. Aikimbayev National Research Center for Especially Dangerous Infections, Almaty, Kazakhstan
| | - Aitbay Bulashev
- Department of Microbiology and Biotechnology, S. Seifullin Kazakh Agrotechnical University, Nur-Sultan, Kazakhstan
| | - Batyrbek Aitzhanov
- Department of Clinical Veterinary Medicine, Kazakh National Agrarian University (KazNAU), Almaty, Kazakhstan
| | - Khairulla Abeuov
- Infectious Disease Monitoring Laboratory, Research Institute for Biological Safety Problems, Gvardeiskiy, Kazakhstan
| | - Abylay Sansyzbay
- Department of Biological Safety, Kazakh National Agrarian University (KazNAU), Almaty, Kazakhstan
| | - Tlektes Yespolov
- International Center for Vaccinology, Kazakh National Agrarian University (KazNAU), Almaty, Kazakhstan
| | - Gourapura J Renukaradhya
- Food Animal Health Research Program, Ohio Agricultural Research and Development Center, Department of Veterinary Preventive Medicine, The Ohio State University (OSU), Wooster, OH, United States
| | - Steven Olsen
- Independent Researcher, McCallsburg, IA, United States
| | - Angel Oñate
- Laboratory of Molecular Immunology, Department of Microbiology, Faculty of Biological Sciences, University of Concepcion, Concepcion, Chile
| | - Kaissar Tabynov
- International Center for Vaccinology, Kazakh National Agrarian University (KazNAU), Almaty, Kazakhstan.,Preclinical Research Laboratory With Vivarium, M. Aikimbayev National Research Center for Especially Dangerous Infections, Almaty, Kazakhstan
| |
Collapse
|
5
|
Development of Human Vectored Brucellosis Vaccine Formulation: Assessment of Safety and Protectiveness of Influenza Viral Vectors Expressing Brucella Immunodominant Proteins in Mice and Guinea Pigs. BIOMED RESEARCH INTERNATIONAL 2020; 2020:1438928. [PMID: 33274194 PMCID: PMC7695499 DOI: 10.1155/2020/1438928] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 07/01/2020] [Revised: 09/10/2020] [Accepted: 10/15/2020] [Indexed: 01/18/2023]
Abstract
In this paper, we first used recombinant influenza viral vector (rIVV) subtype H5N1 expressing from the open reading frame of NS1 80 and NS1 124 amino acids of Brucella outer membrane proteins (Omp) 16 and 19, ribosomal L7/L12, and Cu-Zn superoxide dismutase (SOD) proteins to develop a human brucellosis vaccine. We made 18 combinations of IVVs in mono-, bi-, and tetravalent vaccine formulations and tested them on mice to select the safest and most effective vaccine samples. Then, the most effective vaccine candidates were further tested on guinea pigs. Safety of the rIVV-based vaccine candidate was evaluated by a mouse weight-gain test. Mice and guinea pigs were challenged with the virulent strain B. melitensis 16M. The protective effect of the rIVV-based vaccine candidate was assessed by quantitation of Brucella colonization in tissues and organs of challenged animals. All vaccine formulations were safe in mice. Tested vaccine formulations, as well as the commercial B. melitensis Rev.1 vaccine, have been found to protect mice from B. melitensis 16M infection within the range of 1.6 to 2.97 log10 units (P < 0.05). Tetravalent vaccine formulations from the position of NS1 80 amino acids (0.2 ± 0.4), as well as the commercial B. melitensis Rev.1 vaccine (1.2 ± 2.6), have been found to protect guinea pigs from B. melitensis 16M infection at a significant level (P < 0.05). Thus, tetravalent vaccine formulation Flu-NS1-80-Omp16+Flu-NS1-80-L7/L12+Flu-NS1-80-Omp19+Flu-NS1-80-SOD was chosen as a potential vaccine candidate for further development of an effective human vaccine against brucellosis. These results show a promising future for the development of a safe human vaccine against brucellosis based on rIVVs.
Collapse
|
6
|
Mailybayeva A, Ryskeldinova S, Zinina N, Zhou EM, Renukaradhya GJ, Tabynov K. Evaluation of Duration of Immunogenicity and Protective Efficacy of Improved Influenza Viral Vector-Based Brucella abortus Vaccine Against Brucella melitensis Infection in Sheep and Goats. Front Vet Sci 2020; 7:58. [PMID: 32175335 PMCID: PMC7056664 DOI: 10.3389/fvets.2020.00058] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2019] [Accepted: 01/23/2020] [Indexed: 11/30/2022] Open
Abstract
In this study, we first evaluated the duration of a protective immune response against Brucella melitensis infection in non-pregnant sheep and goats immunized with an improved (by vaccine formulation and route of administration) commercial Brucella abortus vaccine based on influenza viral vectors expressing Brucella immunodominant Omp16, L7/L12, Omp19, or Cu-Zn superoxide dismutase (SOD) proteins (Flu-BA_Omp19-SOD). Sheep and goats in the vaccinated group were immunized thrice concurrently via the subcutaneous and conjunctival routes of administration at an interval of 21 days. Animals in the control group were administered with 20% Montanide Gel01 adjuvant in phosphate-buffered saline in the same way. We showed that the Flu-BA_Omp19-SOD vaccine in sheep and goats induces antigen-specific Th1-biased [immunoglobulin G2a (IgG2a) over IgG1] antibody response and T-cell and interferon γ responses lasting over a period of 1 month post–last vaccination (PLV). The levels of protection against B. melitensis 16M infection (vaccination efficacy) in vaccinated sheep for a period of 6 months were 0–20% and in goats 20–40% compared to control challenge group. But the severity of B. melitensis 16M infection in the Flu-BA_Omp19-SOD–vaccinated sheep and goats during the entire period of observation revealed the infection index (P = 0.001–P < 0.0001) and Brucella colonization in lymph nodes and organs (P = 0.04–P < 0.0001) were significantly lower than those in the control group. To conclude, the Flu-BA_Omp19-SOD vaccine using improved formulation and administration method in sheep and goats provides augmented antigen specific humoral and T-cell immune response lasting only for 1 month PLV and partial protection for 6 months against B. melitensis 16M infection.
Collapse
Affiliation(s)
- Aigerim Mailybayeva
- Laboratory of Infectious Disease Prevention, Research Institute for Biological Safety Problems, Gvardeiskiy, Kazakhstan
| | - Sholpan Ryskeldinova
- Laboratory of Infectious Disease Prevention, Research Institute for Biological Safety Problems, Gvardeiskiy, Kazakhstan
| | - Nadezhda Zinina
- Laboratory of Microbiology, Research Institute for Biological Safety Problems, Gvardeiskiy, Kazakhstan
| | - En-Min Zhou
- Department of Preventive Veterinary Medicine, College of Veterinary Medicine, Northwest A&F University, Yangling, China
| | - Gourapura J Renukaradhya
- Food Animal Health Research Program, Department of Veterinary Preventive Medicine, College of Food Agricultural and Environmental Sciences, The Ohio State University, Wooster, OH, United States
| | - Kaissar Tabynov
- Biological Safety Department, Kazakh National Agrarian University, Almaty, Kazakhstan.,General Clinical Department, Research Institute of Cardiology and Internal Medicine, Almaty, Kazakhstan
| |
Collapse
|
7
|
Hou H, Liu X, Peng Q. The advances in brucellosis vaccines. Vaccine 2019; 37:3981-3988. [PMID: 31176541 DOI: 10.1016/j.vaccine.2019.05.084] [Citation(s) in RCA: 46] [Impact Index Per Article: 9.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2018] [Revised: 05/04/2019] [Accepted: 05/21/2019] [Indexed: 01/18/2023]
Abstract
Brucellosis is a worldwide zoonosis affecting animal and human health. Till now, there is no effective vaccine licensed for brucellosis in humans. Although M5, H38 and 45/20 vaccines were used to prevent animal brucellosis in the early stages, the currently used animal vaccines are S19, Rev.1, S2, RB51 and SR82. However, these vaccines still have several drawbacks such as residual virulence and interfering conventional serological tests. With the development of DNA recombination technologies and the completion of the sequence of Brucella genome, much research focuses on the search for potential safer and more effective vaccines. Preliminary studies have demonstrated that new vaccines, including genetically engineered attenuated vaccines, subunit vaccines and other potential vaccines, have higher levels of protection, but there are still some problems. In this paper, we briefly review the main vaccines that have been used in controlling the brucellosis for decades and the progress in the development of new brucellosis vaccines.
Collapse
Affiliation(s)
- Huanhuan Hou
- Key Laboratory of Zoonosis, Ministry of Education, Institute of Zoonosis, Jilin University, Changchun 130062, China
| | - Xiaofeng Liu
- Tumor Hospital of Jilin Province, Changchun 130021, China
| | - Qisheng Peng
- Key Laboratory of Zoonosis, Ministry of Education, Institute of Zoonosis, Jilin University, Changchun 130062, China.
| |
Collapse
|
8
|
Gerlach T, Elbahesh H, Saletti G, Rimmelzwaan GF. Recombinant influenza A viruses as vaccine vectors. Expert Rev Vaccines 2019; 18:379-392. [PMID: 30777467 DOI: 10.1080/14760584.2019.1582338] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
INTRODUCTION Various viruses, including poxviruses, adenoviruses and vesicular stomatitis virus, have been considered as vaccine vectors for the delivery of antigens of interest in the development of vaccines against newly emerging pathogens. AREAS COVERED Here, we review results that have been obtained with influenza A viruses (IAV) as vaccine vectors. With the advent of reverse genetics technology, IAV-based recombinant vaccine candidates have been constructed that induce protective immunity to a variety of different pathogens of interest, including West Nile virus, Plasmodium falciparum and respiratory syncytial virus. The various cloning strategies to produce effective and attenuated, safe to use IAV-based viral vectors are discussed. EXPERT COMMENTARY It was concluded that IAV-based vector system has several advantages and holds promise for further development.
Collapse
Affiliation(s)
- Thomas Gerlach
- a Research Center for Emerging Infections and Zoonoses (RIZ) , University of Veterinary Medicine Hannover (TiHo) , Hannover , Germany
| | - Husni Elbahesh
- a Research Center for Emerging Infections and Zoonoses (RIZ) , University of Veterinary Medicine Hannover (TiHo) , Hannover , Germany
| | - Giulietta Saletti
- a Research Center for Emerging Infections and Zoonoses (RIZ) , University of Veterinary Medicine Hannover (TiHo) , Hannover , Germany
| | - Guus F Rimmelzwaan
- a Research Center for Emerging Infections and Zoonoses (RIZ) , University of Veterinary Medicine Hannover (TiHo) , Hannover , Germany
| |
Collapse
|
9
|
Gheibi A, Khanahmad H, Kashfi K, Sarmadi M, Khorramizadeh MR. Development of new generation of vaccines for Brucella abortus. Heliyon 2018; 4:e01079. [PMID: 30603712 PMCID: PMC6307385 DOI: 10.1016/j.heliyon.2018.e01079] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2018] [Revised: 12/17/2018] [Accepted: 12/18/2018] [Indexed: 01/18/2023] Open
Abstract
Brucella abortus is a Gram-negative facultative and intracellular bacteria, it causes bovine brucellosis, a zoonotic disease that is responsible for considerable economic loss to owners of domesticated animals and can cause problems in otherwise healthy humans. There are a few available live attenuated vaccines for animal immunization against brucellosis; however, these have significant side effects and offer insufficient protective efficacy. Thus, the need for more research into the Molecular pathobiology and immunological properties of B. abortus that would lead to the development of better and safer vaccines. In this paper we have reviewed the main aspects of the pathology and the responsive immunological mechanisms, we have also covered current and new prospective vaccines against B. abortus.
Collapse
Affiliation(s)
- Azam Gheibi
- Department of Medical Biotechnology, School of Advanced Technologies in Medicine (SATiM), Tehran University of Medical Sciences, Tehran, Iran
| | - Hossein Khanahmad
- Department of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
| | - Khosrow Kashfi
- Department of Molecular, Cellular and Biomedical Sciences, Sophie Davis School of Biomedical Education, City University of New York School of Medicine, New York, USA
| | - Mahdieh Sarmadi
- Department of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
| | - Mohammad Reza Khorramizadeh
- Biosensor Research Center, Endocrinology and Metabolism Molecular-Cellular Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran
| |
Collapse
|
10
|
Tadepalli G, Konduru B, Murali HS, Batra HV. Intraperitoneal administration of a novel chimeric immunogen (rOP) elicits IFN-γ and IL-12p70 protective immune response in BALB/c mice against virulent Brucella. Immunol Lett 2017; 192:79-87. [PMID: 29106986 DOI: 10.1016/j.imlet.2017.10.013] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2017] [Revised: 10/03/2017] [Accepted: 10/24/2017] [Indexed: 02/02/2023]
Abstract
Recombinant engineering of immunologically active chimeric protein consisting of Omp19 and P39 domains of B. abortus (rOP), was purified under denaturing conditions upon expression in E. coli BL21 (DE3) and refolded to dynamic form. The immuno-protective efficacy of rOP was evaluated by challenging the BALB/c mice intraperitoneally (I.P) with the infective species of Brucella in the absence or presence of adjuvants, such as Aluminum hydroxide gel (Al), or Freund's Complete Adjuvant (FCA)/Incomplete Freund's Adjuvant (IFA). Surprisingly, after second boosting, mice received rOP per se were found to be immunogenic in terms of IgG response with the dominant expression of IgG2a and significant IFN-γ by splenic T cells, suggesting that rOP is a strong inducer of anti-Brucella immunity. The resulted anti-rOP antibodies recognized native Omp19 and P39 among species of Brucella with distinct double bands and single band against chimera in immunoblotting. An enhanced and comparable antibody response with varied IgG isotype combinations were noticed in the mice primed and boosted with rOP in adjuvants. However, rOP+FCA/IFA formulation was found to be the most effective in lymphocyte recall assays at inducing significant (P<0.001) proliferation index (P.I.) as well as increased Th1-coupled cytokines (IFN-γ, IL-2 and IL-12p70) than rOP+Al in response to rOP re-stimulation. Furthermore, in vitro defensive assay revealed that compared to anti-rOP antisera, the polyclonal anti-sera from rOP+adjuvants exhibited enhanced protection of RAW264.7 cells against virulent challenge by B. melitensis 16M and B. abortus 544. In addition, compared to sham group, enumeration of Brucella CFU after challenge with the above species showed a significant (P<0.01) reduction of bacteria (log CFU) in the macrophage cell lines and organs of vaccinated mice. On the whole, a relatively higher and faster reduction was noticed in the mice vaccinated with similar amount of purified antigen in Freund's adjuvant. Ability of inducing Th1 directed immune protection in the absence of adjuvant support, postulated rOP as a plausible entrant for developing a chimeric based subunit vaccine against Brucella.
Collapse
Affiliation(s)
- Ganesh Tadepalli
- Department of Microbiology, Defence Food Research Laboratory, Siddarthanagar, Mysore, Karnataka, India.
| | - Balakrishna Konduru
- Department of Microbiology, Defence Food Research Laboratory, Siddarthanagar, Mysore, Karnataka, India
| | | | - Harsh Vardhan Batra
- Department of Microbiology, Defence Food Research Laboratory, Siddarthanagar, Mysore, Karnataka, India
| |
Collapse
|
11
|
Mailybayeva A, Yespembetov B, Ryskeldinova S, Zinina N, Sansyzbay A, Renukaradhya GJ, Petrovsky N, Tabynov K. Improved influenza viral vector based Brucella abortus vaccine induces robust B and T-cell responses and protection against Brucella melitensis infection in pregnant sheep and goats. PLoS One 2017; 12:e0186484. [PMID: 29023541 PMCID: PMC5638537 DOI: 10.1371/journal.pone.0186484] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2017] [Accepted: 10/02/2017] [Indexed: 01/26/2023] Open
Abstract
We previously developed a potent candidate vaccine against bovine brucellosis caused by Brucella abortus using the influenza viral vector expressing Brucella Omp16 and L7/L12 proteins (Flu-BA). Our success in the Flu-BA vaccine trial in cattle and results of a pilot study in non-pregnant small ruminants prompted us in the current study to test its efficacy against B. melitensis infection in pregnant sheep and goats. In this study, we improved the Flu-BA vaccine formulation and immunization method to achieve maximum efficacy and safety. The Flu-BA vaccine formulation had two additional proteins Omp19 and SOD, and administered thrice with 20% Montanide Gel01 adjuvant, simultaneously by both subcutaneous and conjunctival routes at 21 days intervals in pregnant sheep and goats. At 42 days post-vaccination (DPV) we detected antigen-specific IgG antibodies predominantly of IgG2a isotype but also IgG1, and also detected a strong lymphocyte recall response with IFN-γ production. Importantly, our candidate vaccine prevented abortion in 66.7% and 77.8% of pregnant sheep and goats, respectively. Furthermore, complete protection (absence of live B. melitensis 16M) was observed in 55.6% and 66.7% of challenged sheep and goats, and 72.7% and 90.0% of their fetuses (lambs/yeanlings), respectively. The severity of B. melitensis 16M infection in vaccinated sheep and goats and their fetuses (index of infection and rates of Brucella colonization in tissues) was significantly lower than in control groups. None of the protection parameters after vaccination with Flu-BA vaccine were statistically inferior to protection seen with the commercial B. melitensis Rev.1 vaccine (protection against abortion and vaccination efficacy, alpha = 0.18–0.34, infection index, P = 0.37–0.77, Brucella colonization, P = 0.16 to P > 0.99). In conclusion, our improved Flu-BA vaccine formulation and delivery method were found safe and effective in protecting pregnant sheep and goats against adverse consequences of B. melitensis infection.
Collapse
Affiliation(s)
- Aigerim Mailybayeva
- Laboratory of Infectious Disease Prevention, Research Institute for Biological Safety Problems, Zhambulskaya Oblast, Kordaiskiy Rayon, Gvardeiskiy, Republic of Kazakhstan
| | - Bolat Yespembetov
- Laboratory of Microbiology, Research Institute for Biological Safety Problems, Zhambulskaya Oblast, Kordaiskiy Rayon, Gvardeiskiy, Republic of Kazakhstan
| | - Sholpan Ryskeldinova
- Laboratory of Infectious Disease Prevention, Research Institute for Biological Safety Problems, Zhambulskaya Oblast, Kordaiskiy Rayon, Gvardeiskiy, Republic of Kazakhstan
| | - Nadezhda Zinina
- Laboratory of Microbiology, Research Institute for Biological Safety Problems, Zhambulskaya Oblast, Kordaiskiy Rayon, Gvardeiskiy, Republic of Kazakhstan
| | - Abylai Sansyzbay
- Laboratory of Infectious Disease Prevention, Research Institute for Biological Safety Problems, Zhambulskaya Oblast, Kordaiskiy Rayon, Gvardeiskiy, Republic of Kazakhstan
| | - Gourapura J. Renukaradhya
- Food Animal Health Research Program, Ohio Agricultural Research and Development Center, Department of Veterinary Preventive Medicine, The Ohio State University (OSU), Wooster, United States of America
| | | | - Kaissar Tabynov
- Laboratory of Infectious Disease Prevention, Research Institute for Biological Safety Problems, Zhambulskaya Oblast, Kordaiskiy Rayon, Gvardeiskiy, Republic of Kazakhstan
- Vaxine Pty Ltd and Flinders University, Bedford Park, Australia
- * E-mail: ,
| |
Collapse
|
12
|
Tabynov K, Yespembetov B, Matikhan N, Ryskeldinova S, Zinina N, Kydyrbayev Z, Assanzhanova N, Tabynov K, Renukaradhya GJ, Mukhitdinova G, Sansyzbay A. First evaluation of an influenza viral vector based Brucella abortus vaccine in sheep and goats: Assessment of safety, immunogenicity and protective efficacy against Brucella melitensis infection. Vet Microbiol 2016; 197:15-20. [PMID: 27938677 DOI: 10.1016/j.vetmic.2016.11.001] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2016] [Revised: 10/31/2016] [Accepted: 11/01/2016] [Indexed: 01/22/2023]
Abstract
Previously we developed and evaluated a candidate influenza viral vector based Brucella abortus vaccine (Flu-BA) administered with a potent adjuvant Montanide Gel01 in cattle, which was found safe and highly effective. This study was aimed to establish a proof-of-concept of the efficacy of Flu-BA vaccine formulation in sheep and goats. We vaccinated sheep and goats with Flu-BA vaccine and as a positive control vaccinated a group of animals with a commercial B. melitensis Rev.1 vaccine. Clinically, both Flu-BA and Rev.1 vaccines were found safe. Serological analysis showed the animals received Flu-BA vaccine did not induce antibody response against Brucella Omp16 and L7/L12 proteins during the period of our study (56days post-initial vaccination, PIV). But observed significant antigen-specific T cell response indicated by increased lymphocyte stimulation index and enhanced secretion of IFN-γ at day 56 PIV in Flu-BA group. The Flu-BA vaccinated animals completely protected 57.1% of sheep and 42.9% of goats against B. melitensis 16M challenge. The severity of brucellosis in terms of infection index and colonization of Brucella in tissues was significantly lower in the Flu-BA group compared to negative control animals group. Nevertheless, positive control commercial Rev.1 vaccine provided strong antigen-specific T cell immunity and protection against B. melitensis 16M infection. We conclude that the Flu-BA vaccine induces a significant antigen-specific T-cell response and provides complete protection in approximately 50% of sheep and goats against B. melitensis 16M infection. Further investigations are needed to improve the efficacy of Flu-BA and explore its practical application in small ruminants.
Collapse
Affiliation(s)
- Kaissar Tabynov
- The Research Institute for Biological Safety Problems, Zhambulskaya oblast, Kordaiskiy rayon, 080409, Gvardeiskiy, Kazakhstan.
| | - Bolat Yespembetov
- The Research Institute for Biological Safety Problems, Zhambulskaya oblast, Kordaiskiy rayon, 080409, Gvardeiskiy, Kazakhstan
| | - Nurali Matikhan
- Faculty of Veterinary Science, Kazakh National Agrarian University (KazNAU), Almaty 050010, Kazakhstan
| | - Sholpan Ryskeldinova
- The Research Institute for Biological Safety Problems, Zhambulskaya oblast, Kordaiskiy rayon, 080409, Gvardeiskiy, Kazakhstan
| | - Nadezhda Zinina
- The Research Institute for Biological Safety Problems, Zhambulskaya oblast, Kordaiskiy rayon, 080409, Gvardeiskiy, Kazakhstan
| | - Zhailaubay Kydyrbayev
- The Research Institute for Biological Safety Problems, Zhambulskaya oblast, Kordaiskiy rayon, 080409, Gvardeiskiy, Kazakhstan
| | - Nurika Assanzhanova
- The Research Institute for Biological Safety Problems, Zhambulskaya oblast, Kordaiskiy rayon, 080409, Gvardeiskiy, Kazakhstan
| | - Kairat Tabynov
- Faculty of Veterinary Science, Kazakh National Agrarian University (KazNAU), Almaty 050010, Kazakhstan
| | - Gourapura J Renukaradhya
- Food Animal Health Research Program, Ohio Agricultural Research and Development Center, Department of Veterinary Preventive Medicine, The Ohio State University (OSU), Wooster, OH 44691, USA
| | - Gulnara Mukhitdinova
- Faculty of Veterinary Science, Kazakh National Agrarian University (KazNAU), Almaty 050010, Kazakhstan
| | - Abylai Sansyzbay
- The Research Institute for Biological Safety Problems, Zhambulskaya oblast, Kordaiskiy rayon, 080409, Gvardeiskiy, Kazakhstan
| |
Collapse
|
13
|
Simultaneous subcutaneous and conjunctival administration of the influenza viral vector based Brucella abortus vaccine to pregnant heifers provides better protection against B. abortus 544 infection than the commercial B. abortus S19 vaccine. Vaccine 2016; 34:5049-5052. [PMID: 27595898 DOI: 10.1016/j.vaccine.2016.08.072] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2016] [Revised: 08/19/2016] [Accepted: 08/23/2016] [Indexed: 01/03/2023]
Abstract
In this study, we explored possibility of increasing the protective efficacy of our novel influenza viral vector based B. abortus vaccine (Flu-BA) in pregnant heifers by adapting an innovative method of vaccine delivery. We administered the vaccine concurrently via the conjunctival and subcutaneous routes to pregnant heifers, and these routes were previously tested individually. The Flu-BA vaccination of pregnant heifers (n=9) against a challenge B. abortus 544 infection provided protection from abortion, infection of heifers and fetuses/calves by 88.8%, 100% and 100%, respectively (alpha=0.004-0.0007 vs. negative control; n=7). Our candidate vaccine using this delivery method provided slightly better protection than the commercial B. abortus S19 vaccine in pregnant heifers (n=8), which provided protection from abortion, infection of heifers and fetuses/calves by 87.5%, 75% and 87.5%, respectively. This improved method of the Flu-BA vaccine administration is highly recommended for the recovery of farms which has high prevalence of brucellosis.
Collapse
|
14
|
Tabynov K. Influenza viral vector based Brucella abortus vaccine: a novel vaccine candidate for veterinary practice. Expert Rev Vaccines 2016; 15:1237-9. [PMID: 27356589 DOI: 10.1080/14760584.2016.1208089] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Affiliation(s)
- Kaissar Tabynov
- a Laboratory of Infectious Disease Prevention , The Research Institute for Biological Safety Problems, Zhambulskaya oblast, Kordaiskiy rayon , Gvardeisky , Republic of Kazakhstan
| |
Collapse
|